Opioid Induced Constipation Drug Market was valued at US$ 2.51 Mn in 2022 and is expected to reach US$ 3.83 Mn by 2029 at a CAGR of 6.2%. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding the global opioid induced constipation drug market dynamics, structure by identifying and analysing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence.To know about the Research Methodology :- Request Free Sample Report The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the global opioid induced constipation drug market. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis. The number of patients suffering from opioid induced constipation is growing across the globe. Close to 100 mn U.S. patients in 2013 were suffering from opioid induced constipation, according to the American Academy of Pain Medicine. They added that this number is anticipated to increase as the number of people consuming opioid drugs increases. With an increasing awareness of the commercial availability of a large type of opioid drugs, people have resorted to using them for longer terms to treat chronic pains. Increasing incidences of diseases associated with old age, impaired body functions, and rise in the use of medicines such as antidepressants and anticholinergic have collectively led to a high prevalence of constipation among the elderly population. This drives growth in the opioid induced constipation market globally. The use of laxatives for opioid induced constipation is a major challenge that is reducing sales of approved drugs meant for the treatment of opioid induced constipation. Lubiprostone segment is leading the global opioid induced constipation drug market. Lubiprostone under the brand name Amitiza is indicated for treating opioid induced constipation drug, where it major indication is for chronic idiopathic constipation (CIC). Lubiprostone is projected that the segment will take over the market share of methylnaltrexone bromide. Moreover, naloxegol is expected to grow at highest CAGR over the forecast period. The drug is under testing for many patient types such as pregnant women and patients less than 17 years of age. So, future approvals are expected to lead the market. Region-wise, North America is the dominant regional opioid induced constipation drugs market through the forecast period. Early bird approval of opioid induced constipation drugs by the USFDA and high consumption of opioids in the US is the prime growth factors for the opioid induced constipation drugs market in North America. Besides, Germany, UK, and Spain are the major countries setting the market dynamics in Europe. Overall, the developed countries across the world, predominantly North America and Europe are the key consumers of opioid induced constipation drugs.
Scope of Global Opioid Induced Constipation Drug Market: Inquire before buying
Global Opioid Induced Constipation Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 2.51 Mn. Forecast Period 2023 to 2029 CAGR: 6.2% Market Size in 2029: US $ 3.83 Mn. Segments Covered: by Prescription Prescribed Over The Counter by Type Methylnaltrexone Bromide Lubiprostone Naloxegol Naldemedine Docusate Sodium Others Opioid Induced Constipation Drug Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Key players operating in Global Opioid Induced Constipation Drug Market
1. GlaxoSmithKline, Inc. 2. AstraZeneca plc, Inc. 3. Pfizer, Inc. 4. S.L.A. Pharma AG 5. AIKO Biotechnology 6. Cubist Pharmaceuticals 7. Salix Pharmaceuticals, Inc. 8. Takeda Pharmaceutical Company Limited 9. Shionogo & Co Ltd. 10.Daiichi Sankyo Co., Ltd. 11.Ironwood Pharmaceuticals, Inc. 12.Progenics Pharmaceuticals, Inc. 13.Sucampo Pharmaceuticals, Inc. 14.Synergy Pharmaceuticals, Inc. Frequently Asked Questions: 1. Which region has the largest share in Global Opioid Induced Constipation Market? Ans: North America region holds the highest share in 2022. 2. What is the growth rate of Global Opioid Induced Constipation Market? Ans: The Global Opioid Induced Constipation Drug Market is growing at a CAGR of 6.2% during forecasting period 2023-2029. 3. What is scope of the Global Opioid Induced Constipation Market report? Ans: Global Opioid Induced Constipation Drug Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. What is the study period of this market? Ans: The Global Opioid Induced Constipation Drug Market is studied from 2022 to 2029.
1. Opioid Induced Constipation Drug Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Opioid Induced Constipation Drug Market: Dynamics 2.1. Opioid Induced Constipation Drug Market Trends by Region 2.1.1. North America Opioid Induced Constipation Drug Market Trends 2.1.2. Europe Opioid Induced Constipation Drug Market Trends 2.1.3. Asia Pacific Opioid Induced Constipation Drug Market Trends 2.1.4. Middle East and Africa Opioid Induced Constipation Drug Market Trends 2.1.5. South America Opioid Induced Constipation Drug Market Trends 2.2. Opioid Induced Constipation Drug Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Opioid Induced Constipation Drug Market Drivers 2.2.1.2. North America Opioid Induced Constipation Drug Market Restraints 2.2.1.3. North America Opioid Induced Constipation Drug Market Opportunities 2.2.1.4. North America Opioid Induced Constipation Drug Market Challenges 2.2.2. Europe 2.2.2.1. Europe Opioid Induced Constipation Drug Market Drivers 2.2.2.2. Europe Opioid Induced Constipation Drug Market Restraints 2.2.2.3. Europe Opioid Induced Constipation Drug Market Opportunities 2.2.2.4. Europe Opioid Induced Constipation Drug Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Opioid Induced Constipation Drug Market Drivers 2.2.3.2. Asia Pacific Opioid Induced Constipation Drug Market Restraints 2.2.3.3. Asia Pacific Opioid Induced Constipation Drug Market Opportunities 2.2.3.4. Asia Pacific Opioid Induced Constipation Drug Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Opioid Induced Constipation Drug Market Drivers 2.2.4.2. Middle East and Africa Opioid Induced Constipation Drug Market Restraints 2.2.4.3. Middle East and Africa Opioid Induced Constipation Drug Market Opportunities 2.2.4.4. Middle East and Africa Opioid Induced Constipation Drug Market Challenges 2.2.5. South America 2.2.5.1. South America Opioid Induced Constipation Drug Market Drivers 2.2.5.2. South America Opioid Induced Constipation Drug Market Restraints 2.2.5.3. South America Opioid Induced Constipation Drug Market Opportunities 2.2.5.4. South America Opioid Induced Constipation Drug Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Opioid Induced Constipation Drug Industry 2.8. Analysis of Government Schemes and Initiatives For Opioid Induced Constipation Drug Industry 2.9. Opioid Induced Constipation Drug Market Trade Analysis 2.10. The Global Pandemic Impact on Opioid Induced Constipation Drug Market 3. Opioid Induced Constipation Drug Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2022-2029 3.1. Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 3.1.1. Prescribed 3.1.2. Over The Counter 3.2. Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 3.2.1. Methylnaltrexone Bromide 3.2.2. Lubiprostone 3.2.3. Naloxegol 3.2.4. Naldemedine 3.2.5. Docusate Sodium 3.2.6. Others 3.3. Opioid Induced Constipation Drug Market Size and Forecast, by Region (2022-2029) 3.3.1. North America 3.3.2. Europe 3.3.3. Asia Pacific 3.3.4. Middle East and Africa 3.3.5. South America 4. North America Opioid Induced Constipation Drug Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 4.1. North America Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 4.1.1. Prescribed 4.1.2. Over The Counter 4.2. North America Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 4.2.1. Methylnaltrexone Bromide 4.2.2. Lubiprostone 4.2.3. Naloxegol 4.2.4. Naldemedine 4.2.5. Docusate Sodium 4.2.6. Others 4.3. North America Opioid Induced Constipation Drug Market Size and Forecast, by Country (2022-2029) 4.3.1. United States 4.3.1.1. United States Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 4.3.1.1.1. Prescribed 4.3.1.1.2. Over The Counter 4.3.1.2. United States Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 4.3.1.2.1. Methylnaltrexone Bromide 4.3.1.2.2. Lubiprostone 4.3.1.2.3. Naloxegol 4.3.1.2.4. Naldemedine 4.3.1.2.5. Docusate Sodium 4.3.1.2.6. Others 4.3.2. Canada 4.3.2.1. Canada Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 4.3.2.1.1. Prescribed 4.3.2.1.2. Over The Counter 4.3.2.2. Canada Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 4.3.2.2.1. Methylnaltrexone Bromide 4.3.2.2.2. Lubiprostone 4.3.2.2.3. Naloxegol 4.3.2.2.4. Naldemedine 4.3.2.2.5. Docusate Sodium 4.3.2.2.6. Others 4.3.3. Mexico 4.3.3.1. Mexico Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 4.3.3.1.1. Prescribed 4.3.3.1.2. Over The Counter 4.3.3.2. Mexico Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 4.3.3.2.1. Methylnaltrexone Bromide 4.3.3.2.2. Lubiprostone 4.3.3.2.3. Naloxegol 4.3.3.2.4. Naldemedine 4.3.3.2.5. Docusate Sodium 4.3.3.2.6. Others 5. Europe Opioid Induced Constipation Drug Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 5.1. Europe Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 5.2. Europe Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 5.3. Europe Opioid Induced Constipation Drug Market Size and Forecast, by Country (2022-2029) 5.3.1. United Kingdom 5.3.1.1. United Kingdom Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 5.3.1.2. United Kingdom Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 5.3.2. France 5.3.2.1. France Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 5.3.2.2. France Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 5.3.3. Germany 5.3.3.1. Germany Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 5.3.3.2. Germany Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 5.3.4. Italy 5.3.4.1. Italy Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 5.3.4.2. Italy Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 5.3.5. Spain 5.3.5.1. Spain Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 5.3.5.2. Spain Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 5.3.6. Sweden 5.3.6.1. Sweden Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 5.3.6.2. Sweden Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 5.3.7. Austria 5.3.7.1. Austria Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 5.3.7.2. Austria Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 5.3.8. Rest of Europe 5.3.8.1. Rest of Europe Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 5.3.8.2. Rest of Europe Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 6. Asia Pacific Opioid Induced Constipation Drug Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 6.1. Asia Pacific Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 6.2. Asia Pacific Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 6.3. Asia Pacific Opioid Induced Constipation Drug Market Size and Forecast, by Country (2022-2029) 6.3.1. China 6.3.1.1. China Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 6.3.1.2. China Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 6.3.2. S Korea 6.3.2.1. S Korea Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 6.3.2.2. S Korea Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 6.3.3. Japan 6.3.3.1. Japan Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 6.3.3.2. Japan Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 6.3.4. India 6.3.4.1. India Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 6.3.4.2. India Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 6.3.5. Australia 6.3.5.1. Australia Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 6.3.5.2. Australia Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 6.3.6. Indonesia 6.3.6.1. Indonesia Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 6.3.6.2. Indonesia Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 6.3.7. Malaysia 6.3.7.1. Malaysia Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 6.3.7.2. Malaysia Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 6.3.8. Vietnam 6.3.8.1. Vietnam Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 6.3.8.2. Vietnam Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 6.3.9. Taiwan 6.3.9.1. Taiwan Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 6.3.9.2. Taiwan Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 6.3.10. Rest of Asia Pacific 6.3.10.1. Rest of Asia Pacific Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 6.3.10.2. Rest of Asia Pacific Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 7. Middle East and Africa Opioid Induced Constipation Drug Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 7.1. Middle East and Africa Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 7.2. Middle East and Africa Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 7.3. Middle East and Africa Opioid Induced Constipation Drug Market Size and Forecast, by Country (2022-2029) 7.3.1. South Africa 7.3.1.1. South Africa Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 7.3.1.2. South Africa Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 7.3.2. GCC 7.3.2.1. GCC Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 7.3.2.2. GCC Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 7.3.3. Nigeria 7.3.3.1. Nigeria Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 7.3.3.2. Nigeria Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 7.3.4. Rest of ME&A 7.3.4.1. Rest of ME&A Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 7.3.4.2. Rest of ME&A Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 8. South America Opioid Induced Constipation Drug Market Size and Forecast by Segmentation (by Value in USD Million) 2022-2029 8.1. South America Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 8.2. South America Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 8.3. South America Opioid Induced Constipation Drug Market Size and Forecast, by Country (2022-2029) 8.3.1. Brazil 8.3.1.1. Brazil Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 8.3.1.2. Brazil Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 8.3.2. Argentina 8.3.2.1. Argentina Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 8.3.2.2. Argentina Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 8.3.3. Rest Of South America 8.3.3.1. Rest Of South America Opioid Induced Constipation Drug Market Size and Forecast, by Prescription (2022-2029) 8.3.3.2. Rest Of South America Opioid Induced Constipation Drug Market Size and Forecast, by Type (2022-2029) 9. Global Opioid Induced Constipation Drug Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Opioid Induced Constipation Drug Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. GlaxoSmithKline, Inc. 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. AstraZeneca plc, Inc. 10.3. Pfizer, Inc. 10.4. S.L.A. Pharma AG 10.5. AIKO Biotechnology 10.6. Cubist Pharmaceuticals 10.7. Salix Pharmaceuticals, Inc. 10.8. Takeda Pharmaceutical Company Limited 10.9. Shionogo & Co Ltd. 10.10. Daiichi Sankyo Co., Ltd. 10.11. Ironwood Pharmaceuticals, Inc. 10.12. Progenics Pharmaceuticals, Inc. 10.13. Sucampo Pharmaceuticals, Inc. 10.14. Synergy Pharmaceuticals, Inc. 11. Key Findings 12. Industry Recommendations 13. Opioid Induced Constipation Drug Market: Research Methodology 14. Terms and Glossary